IP Library Granted Patent US 10,821,283
Granted Patent B2
US 10,821,283 · App. 15/478,066 · Granted Nov 3, 2020

Reducing motility of cancer cells using tumor treating fields (TTFields)

Inventors: Moshe Giladi (Moshav Herut, IL); Rosa S. Shnaiderman (Haifa, IL)
Assignee: Novocure GmbH
A61N1/32A61N1/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,821,283
App. No.
15/478,066
Granted
Nov 3, 2020
Kind
B2
Abstract

The spreading of cancer cells in a target region can be inhibited by imposing a first AC electric field in the target region for a first interval of time, with a frequency and amplitude selected to disrupt mitosis of the cancer cells; and imposing a second AC electric field in the target region for a second interval of time, with a frequency and the amplitude selected to reduce motility of the cancer cells. The amplitude of the second AC electric field is lower than the amplitude of the first AC electric field.

Claims (31)

1. A method of inhibiting spreading of cancer cells in a target region, the method comprising:

(a) imposing a first AC electric field in the target region for a first interval of time, the first AC electric field having a first frequency and a first amplitude, wherein the first frequency and the first amplitude are selected so that the first AC electric field disrupts mitosis of the cancer cells;

(b) imposing a second AC electric field in the target region for a second interval of time, the second AC electric field having a second frequency and a second amplitude, wherein the second frequency and the second amplitude are selected so that the second AC electric field reduces motility of the cancer cells, and wherein the second amplitude is lower than the first amplitude; and

(c) continuously repeating step (a) and step (b) in an alternating sequence during a course of treatment.

2. The method of claim 1 , wherein the second amplitude is less than 75% of the first amplitude.

3. The method of claim 2 , wherein the first interval of time is less than 5 seconds, and wherein the second interval of time is less than 5 seconds.

4. The method of claim 3 , wherein the course of treatment has a duration of at least 12 hours.

5. The method of claim 1 , wherein the second frequency and the first frequency are different.

6. The method of claim 1 , wherein the first frequency is 200 kHz±10% and the second frequency is 300 kHz±10%.

7. The method of claim 1 , further comprising a step of administering a compound that inhibits cell mobility during the course of treatment.

8. The method of claim 7 , wherein the compound comprises Bumetanide.

9. The method of claim 1 , wherein the second amplitude is at least 0.6 V/cm RMS.

10. The method of claim 1 , wherein the second amplitude is less than 75% of the first amplitude, wherein the second frequency and the first frequency are different, wherein the first interval of time is less than 5 seconds, wherein the second interval of time is less than 5 seconds, and wherein the second amplitude is at least 0.6 V/cm RMS.

11. The method of claim 10 , wherein the first frequency is 200 kHz±10% and the second frequency is 300 kHz±10%.

12. The method of claim 1 , wherein the first AC electric field is imposed in the target region in a first direction for a first portion of the first interval of time,

wherein the first AC electric field is imposed in the target region in a second direction for a second portion of the first interval of time, and

wherein an angle between the first direction and the second direction is between 60° and 90°.

13. The method of claim 12 , wherein the second AC electric field is imposed in the target region in the first direction for a first portion of the second interval of time, and

wherein the second AC electric field is imposed in the target region in the second direction for a second portion of the second interval of time.

14. The method of claim 13 , wherein the second amplitude is less than 75% of the first amplitude.

15. The method of claim 14 , wherein the second frequency and the first frequency are different, wherein the first interval of time is less than 5 seconds, and wherein the second interval of time is less than 5 seconds.

16. The method of claim 1 , wherein a direction of the first AC electric field is changed during at least some of the repeating steps, and wherein a direction of the second AC electric field is changed during at least some of the repeating steps.

17. The method of claim 16 , wherein the second amplitude is less than 75% of the first amplitude.

18. The method of claim 17 , wherein the second frequency and the first frequency are different, wherein the first interval of time is less than 5 seconds, and wherein the second interval of time is less than 5 seconds.

19. An apparatus for inhibiting spreading of cancer cells in a target region, the apparatus comprising:

an AC signal generator having (i) a first controllable output configured to apply an AC voltage across a first set of capacitively coupled electrodes that are positioned in a vicinity of the target region, so as to impose an electric field in the target region in a first direction and (ii) a second controllable output configured to apply an AC voltage across a second set of capacitively coupled electrodes that are positioned in the vicinity of the target region, so as to impose an electric field in the target region in a second direction; and

a controller configured to (a) control the first controllable output so that a first AC signal is generated for a first interval of time, the first AC signal having a first frequency and a first amplitude, wherein the first frequency and the first amplitude are selected to impose an electric field that disrupts mitosis of the cancer cells, and (b) control the first controllable output so that a second AC signal is generated for a second interval of time, the second AC signal having a second frequency and a second amplitude, wherein the second frequency and the second amplitude are selected to impose an electric field that reduces motility of the cancer cells, and wherein the second amplitude is lower than the first amplitude, (c) control the second controllable output so that a third AC signal is generated for a third interval of time, the third AC signal having a third frequency and a third amplitude, wherein the third frequency and the third amplitude are selected to impose an electric field that disrupts mitosis of the cancer cells, and (d) control the second controllable output so that a fourth AC signal is generated for a fourth interval of time, the fourth AC signal having a fourth frequency and a fourth amplitude, wherein the fourth frequency and the fourth amplitude are selected to impose an electric field that reduces motility of the cancer cells, and wherein the fourth amplitude is lower than the third amplitude, and (e) continuously repeat (a) through (d) in an alternating sequence during a course of treatment.

20. The apparatus of claim 19 , wherein the second amplitude is less than 75% of the first amplitude and wherein the fourth amplitude is less than 75% of the third amplitude.

21. The apparatus of claim 19 , wherein the second frequency and the first frequency are different, and wherein the fourth frequency and the third frequency are different.

22. The apparatus of claim 19 , wherein the second amplitude is less than 75% of the first amplitude and wherein the fourth amplitude is less than 75% of the third amplitude, wherein the second frequency and the first frequency are different, wherein the fourth frequency and the third frequency are different, wherein the third frequency is the same as the first frequency, wherein the fourth frequency is the same as the second frequency, wherein the first interval of time is less than 5 seconds, wherein the second interval of time is less than 5 seconds, wherein the third interval of time is less than 5 seconds, and wherein the fourth interval of time is less than 5 seconds.

23. The apparatus of claim 19 , wherein the first frequency is 200 kHz±10%, the second frequency is 300 kHz±10%, the third frequency is 200 kHz±10%, and the fourth frequency is 300 kHz±10%.

Assignments (12)
PATENT SECURITY AGREEMENT Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2024
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NOVOCURE GMBH
Reel/Frame 067211/0839 →
SECURITY INTEREST Recorded Nov 6, 2020
From: NOVOCURE GMBH
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 054344/0510 →
SUPPLEMENTAL RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 45284 0851 Recorded Aug 25, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 053597/0253 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 45278 0825 Recorded Aug 25, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 053597/0335 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 50395/0398 Recorded Aug 19, 2020
From: BPCR LIMITED PARTNERSHIP
To: NOVOCURE GMBH
Reel/Frame 053538/0623 →
OMNIBUS CONFIRMATION OF ASSIGNMENT AGREEMENT Recorded May 21, 2020
From: BIOPHARMA CREDIT PLC
To: BPCR LIMITED PARTNERSHIP
Reel/Frame 052741/0173 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2019
From: NOVOCURE LIMITED
To: NOVOCURE GMBH
Reel/Frame 050110/0098 →
SECURITY INTEREST Recorded May 6, 2019
From: NOVOCURE GMBH
To: BIOPHARMA CREDIT PLC
Reel/Frame 050395/0398 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045278/0825 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045284/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2018
From: GILADI, MOSHE; SHNAIDERMAN, ROSA S.
To: NOVOCURE LIMITED
Reel/Frame 044570/0151 →
Continuity (2)
Provisional Application 62317985 · Apr 4, 2016
Related Publication 20170281934A1 · Oct 5, 2017
Cited By (5)
US 12,208,275 US 12,220,575 US 12,311,136 US 12,343,336 US 12,434,053